Deep Dive: Deep Dive Into Bevacizumab Biosimilars for Eye Conditions

As use of reference bevacizumab (Avastin) for the treatment of macular degeneration has increased over the past decade, payers have begun to recommend bevacizumab biosimilars for the same indication. However, some institutions, including the American Academy of Ophthalmology, say that there needs to be more evidence for the use of these biosimilars for macular degeneration and that recommending them for use is premature.